Hyperion rises 13.4% on Ravicti data publication
This article was originally published in Scrip
Hyperion Therapeutics ended the day at a new high on 25 February, gaining 13.4% to close at $31.41 per share based on newly published data for Ravicti (glycerol phenylbutyrate) in the treatment of hepatic encephalopathy (HE) and the company's Phase III update.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.